FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W1979770418> ?p ?o ?g. }

• W1979770418 endingPage "395" @default.
• W1979770418 startingPage "388" @default.
• W1979770418 abstract "Objective Based on the short-term results of the AIDS Clinical Trials Group (ACTG) A5095 trial, zidovudine (ZDV)/lamivudine (3TC)/abacavir (ABC) is no longer recommended as a first-line antiretroviral regimen. Data on the efficacy of this triple nucleoside reverse transcriptase inhibitor (NRTI) combination compared with the gold-standard nonnucleoside reverse transcriptase inhibitor (NNRTI) regimen could provide important information. Methods Patients were selected from three prospective cohorts of patients who received first-line therapy with ZDV/3TC plus an NNRTI or ABC, started after January 1998. Immunovirological changes and the proportion of treatment discontinuations were compared between groups. Results Of the 380 patients, 190 started on ABC [the triple-NRTI group (3N)] and 190 on NNRTI. At baseline, there was no statistical difference between the NNRTI and 3N groups for age (mean=38 years), sex (66% male) or CD4 cell count (mean=305 cells/μL). Mean baseline plasma HIV-1 viral load (pVL) was higher in the 3N group (4.6 vs. 4.3 log10 HIV-1 RNA copies/mL: P<0.01). Lower and higher estimates of median pVL decrease at month 24 were 2.05 and 4.76 log10 copies/mL in the 3N group, and 1.73 and 4.31 log10 copies/mL in the NNRTI group (not significant). CD4 cell count evolution did not differ between groups. Treatment discontinuation occurred in 45% vs. 44% of patients in the NNRTI and 3N groups, respectively, after median durations of 9 and 4 months, respectively (P=0.02). Conclusions In this prospective cohort, 3N and NNRTI regimens as first-line therapy produced similar immunovirological responses." @default.
• W1979770418 created "2016-06-24" @default.
• W1979770418 creator A5000420787 @default.
• W1979770418 creator A5005288167 @default.
• W1979770418 creator A5025818776 @default.
• W1979770418 creator A5040159137 @default.
• W1979770418 creator A5056512475 @default.
• W1979770418 creator A5060353319 @default.
• W1979770418 creator A5068872303 @default.
• W1979770418 creator A5073407932 @default.
• W1979770418 creator A5077270648 @default.
• W1979770418 date "2005-11-01" @default.
• W1979770418 modified "2023-10-14" @default.
• W1979770418 title "Triple nucleoside reverse transcriptase inhibitor- vs. nonnucleoside reverse transcriptase inhibitor-containing regimens as first-line therapy: efficacy and durability in a prospective cohort of French HIV-infected patients" @default.
• W1979770418 cites W142854403 @default.
• W1979770418 cites W1859737084 @default.
• W1979770418 cites W1964491830 @default.
• W1979770418 cites W1978540833 @default.
• W1979770418 cites W1993086185 @default.
• W1979770418 cites W1993775483 @default.
• W1979770418 cites W2004293828 @default.
• W1979770418 cites W2013788600 @default.
• W1979770418 cites W2035857470 @default.
• W1979770418 cites W2064923846 @default.
• W1979770418 cites W2072753555 @default.
• W1979770418 cites W2100235072 @default.
• W1979770418 cites W2145897295 @default.
• W1979770418 cites W2324224482 @default.
• W1979770418 cites W2327498456 @default.
• W1979770418 cites W4239796430 @default.
• W1979770418 doi "https://doi.org/10.1111/j.1468-1293.2005.00315.x" @default.
• W1979770418 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/16268820" @default.
• W1979770418 hasPublicationYear "2005" @default.
• W1979770418 type Work @default.
• W1979770418 sameAs 1979770418 @default.
• W1979770418 citedByCount "5" @default.
• W1979770418 countsByYear W19797704182013 @default.
• W1979770418 crossrefType "journal-article" @default.
• W1979770418 hasAuthorship W1979770418A5000420787 @default.
• W1979770418 hasAuthorship W1979770418A5005288167 @default.
• W1979770418 hasAuthorship W1979770418A5025818776 @default.
• W1979770418 hasAuthorship W1979770418A5040159137 @default.
• W1979770418 hasAuthorship W1979770418A5056512475 @default.
• W1979770418 hasAuthorship W1979770418A5060353319 @default.
• W1979770418 hasAuthorship W1979770418A5068872303 @default.
• W1979770418 hasAuthorship W1979770418A5073407932 @default.
• W1979770418 hasAuthorship W1979770418A5077270648 @default.
• W1979770418 hasBestOaLocation W19797704181 @default.
• W1979770418 hasConcept C126322002 @default.
• W1979770418 hasConcept C142462285 @default.
• W1979770418 hasConcept C159047783 @default.
• W1979770418 hasConcept C188816634 @default.
• W1979770418 hasConcept C2522874641 @default.
• W1979770418 hasConcept C2777351918 @default.
• W1979770418 hasConcept C2777869810 @default.
• W1979770418 hasConcept C2778715236 @default.
• W1979770418 hasConcept C2779465607 @default.
• W1979770418 hasConcept C2780216070 @default.
• W1979770418 hasConcept C2780593183 @default.
• W1979770418 hasConcept C2780727368 @default.
• W1979770418 hasConcept C2781413609 @default.
• W1979770418 hasConcept C2909970146 @default.
• W1979770418 hasConcept C2993143319 @default.
• W1979770418 hasConcept C3013748606 @default.
• W1979770418 hasConcept C71924100 @default.
• W1979770418 hasConcept C72563966 @default.
• W1979770418 hasConcept C90924648 @default.
• W1979770418 hasConceptScore W1979770418C126322002 @default.
• W1979770418 hasConceptScore W1979770418C142462285 @default.
• W1979770418 hasConceptScore W1979770418C159047783 @default.
• W1979770418 hasConceptScore W1979770418C188816634 @default.
• W1979770418 hasConceptScore W1979770418C2522874641 @default.
• W1979770418 hasConceptScore W1979770418C2777351918 @default.
• W1979770418 hasConceptScore W1979770418C2777869810 @default.
• W1979770418 hasConceptScore W1979770418C2778715236 @default.
• W1979770418 hasConceptScore W1979770418C2779465607 @default.
• W1979770418 hasConceptScore W1979770418C2780216070 @default.
• W1979770418 hasConceptScore W1979770418C2780593183 @default.
• W1979770418 hasConceptScore W1979770418C2780727368 @default.
• W1979770418 hasConceptScore W1979770418C2781413609 @default.
• W1979770418 hasConceptScore W1979770418C2909970146 @default.
• W1979770418 hasConceptScore W1979770418C2993143319 @default.
• W1979770418 hasConceptScore W1979770418C3013748606 @default.
• W1979770418 hasConceptScore W1979770418C71924100 @default.
• W1979770418 hasConceptScore W1979770418C72563966 @default.
• W1979770418 hasConceptScore W1979770418C90924648 @default.
• W1979770418 hasIssue "6" @default.
• W1979770418 hasLocation W19797704181 @default.
• W1979770418 hasLocation W19797704182 @default.
• W1979770418 hasOpenAccess W1979770418 @default.
• W1979770418 hasPrimaryLocation W19797704181 @default.
• W1979770418 hasRelatedWork W1978873194 @default.
• W1979770418 hasRelatedWork W1979770418 @default.
• W1979770418 hasRelatedWork W1993848347 @default.
• W1979770418 hasRelatedWork W2009577475 @default.
• W1979770418 hasRelatedWork W2032073239 @default.
• W1979770418 hasRelatedWork W2061761182 @default.
• W1979770418 hasRelatedWork W2100307468 @default.

• next